Skip to main content

Table 2 Univariate Cox regression analysis of KLK12 mRNA expression in relation to patients’ outcome in triple-negative breast cancer

From: Prognostic value of kallikrein-related peptidase 12 (KLK12) mRNA expression in triple-negative breast cancer patients

Clinical parametersOSDFS
No.aHR (95% CI)bpNo.aHR (95% CI)bp
Age  <  0.001  0.001
 ≤ 60 years671 671 
 > 60 years582.96 (1.63–5.36) 562.45 (1.42–4.23) 
Lymph node status  0.055  0.118
 N0701 691 
 N1/N2/N3551.74 (0.99–3.07) 541.53 (0.90–2.59) 
Tumor size  0.117  0.204
 ≤ 20 mm331 331 
 > 20 mm911.83 (0.86–3.92) 891.54 (0.79–2.98) 
Histological grade  0.915  0.600
 II211 211 
 III1041.04 (0.49–2.23) 1021.22 (0.58–2.59) 
KLK12 mRNAc  0.037  0.010
 Negative611 591 
 Positive541.91 (1.04–3.50) 542.12 (1.19–3.78) 
KLK12 mRNA posd  0.047  0.051
 Low161 161 
 High382.98 (1.02–8.74) 382.64 (1.00–6.96) 
  1. Significant p-values (p ≤ 0.05) are indicated in bold, trends towards significance (p ≤ 0.06) in italics
  2. Due to missing values, numbers do not always add up to n = 125 (OS) and n = 123 (DFS), when the whole cohort is analyzed
  3. a Number of patients
  4. bHR Hazard ratio (CI Confidence interval) of univariate Cox regression analysis
  5. c Dichotomized into positive and negative expression
  6. d Positive KLK12 mRNA values were dichotomized into low and high expression by the 30th percentile